Insights
Insights From Our Experts
Articles
Staying Ahead of the Curve in Pharmacovigilance: Module VI Addendum II – Masking of Personal Data in Individual Case Safety (GVP)
In an era where patient safety and regulatory compliance are more critical than ever, staying informed about global pharmacovigilance trends is essential. The EMA and PRAC recently released the “Module VI Addendum II – Masking of…
Insights from BIO with OS Therapies
At this year’s BIO International Convention 2025, pharmaphorum’s Jonah Comstock sat down with Paul Romness, CEO of OS Therapies, and Farah Ahmad, VP of Business Development at EVERSANA, to explore how emerging biotech companies are navigating…
Case Study: Transforming Market Access with NAVLIN Insights KPI
How one global pharma team turned fragmented pricing data into strategic power. In a complex launch environment, pricing and market access teams face mounting pressure to deliver insights that resonate with CEOs, affiliates, payers, and investors.…
Pharmatizing AI & EVERSANA’s Bold Vision for Its AI Accelerator
EVERSANA continues to redefine the future of pharmaceutical commercialization with its newly launched AI Accelerator—a dedicated center of excellence designed to embed artificial intelligence across every touchpoint of the life sciences value chain. Spearheaded by Chief…
Empowering Scientific Dialogue: Key Takeaways from the FDA’s SIUU Guidance
Posted by
Anne Marie Robertson , Tim Lewis , Susan Giacalone, MSN, BCMAS, MSL-BC on July 21, 20257/21/25
Discover the latest insights from the FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU). This comprehensive document provides a clarified framework for pharmaceutical companies to share scientifically sound information with healthcare providers. In this…
Bridging the Evidence Gap in Hereditary Angioedema (HAE): Indirect Comparison Highlights Garadacimab’s Potential
Hereditary angioedema (HAE) is a rare, debilitating condition marked by unpredictable and potentially life-threatening swelling episodes. While long-term prophylactic therapies have significantly improved disease management, selecting the optimal treatment remains complex—particularly in the absence of direct…
Where Process Meets Profit: How Strategic Order to Cash Drives Real Revenue Outcomes
Is your Order to Cash (OTC) process helping you maximize revenue—or quietly leaking it? In their latest article, EVERSANA experts Christina Christos and Jim Burke explore how pharmaceutical manufacturers can align OTC and Revenue Management to…
Navigating the Not-So-Direct Path to Access – A Pharmacist’s Perspective
Originally published on Drug Channels July 11, 2025 The traditional healthcare system built for yesterday’s healthcare doesn’t serve today’s patients or advanced therapies. Lindsay Reel, VP of Pharmacy Practice & Specialty at EVERSANA, shares her frontline…
Staying Ahead of the Curve in Pharmacovigilance: Inspection Metrics Report for 2023 by Egyptian Drug Authority (EDA)
In an era where patient safety and regulatory compliance are more critical than ever, staying informed about global pharmacovigilance trends is essential. The Egyptian Drug Authority (EDA) recently released its 2023 Pharmacovigilance Inspection Metrics Report, offering…
Staying Ahead of the Curve in Pharmacovigilance: ANVISA RDC No. 967/25
As the regulatory landscape continues to evolve, staying compliant with new pharmacovigilance requirements is more important than ever. Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. What You Need to Know About…